{
  "trial_id": "NCT00394082",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, ECOG performance status, HER-2 status, prior anthracycline exposure, left ventricle ejection fraction, electrocardiogram (ECG) results, prior radiotherapy, International Normalized Ratio (INR), activated partial thromboplastin time (APTT), absolute neutrophil count (ANC), platelet count, hemoglobin (Hgb) level, aspartate aminotransferase (AST or SGOT) level, alanine aminotransferase (ALT or SGPT) level, total bilirubin level, creatinine level, pregnancy test results, use of effective contraception, history of chemotherapy for metastatic or locally recurrent disease, history of neo-adjuvant chemotherapy, history of taxane-based adjuvant therapy, history of non-taxane-based adjuvant therapy, concurrent immunotherapy or hormonal therapy, presence of parenchymal brain metastases, blood pressure, history of congestive heart failure, history of coagulopathy or bleeding diathesis, use of therapeutic anticoagulation, urine protein:creatinine ratio, history of cerebrovascular accident, history of peripheral vascular disease, history of cardiovascular disease, history of abdominal fistula or gastrointestinal perforation, presence of non-healing wound, ulcer, or bone fracture, history of major surgical procedure, history of other malignancy, participation in an experimental drug study, pregnancy or nursing status, presence of sensory neuropathy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Weight",
        "Menopausal status",
        "Time from First Documented Metastasis/Relapse to Study Entry",
        "Dominant Current Site of Metastasis/Relapse"
      ],
      "remaining_candidate_features": [
        "HER-2 status",
        "prior anthracycline exposure",
        "left ventricle ejection fraction",
        "electrocardiogram (ECG) results",
        "prior radiotherapy",
        "International Normalized Ratio (INR)",
        "activated partial thromboplastin time (APTT)",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "hemoglobin (Hgb) level",
        "aspartate aminotransferase (AST or SGOT) level",
        "alanine aminotransferase (ALT or SGPT) level",
        "total bilirubin level",
        "creatinine level",
        "pregnancy test results",
        "use of effective contraception",
        "history of chemotherapy for metastatic or locally recurrent disease",
        "history of neo-adjuvant chemotherapy",
        "history of taxane-based adjuvant therapy",
        "history of non-taxane-based adjuvant therapy",
        "concurrent immunotherapy or hormonal therapy",
        "presence of parenchymal brain metastases",
        "blood pressure",
        "history of congestive heart failure",
        "history of coagulopathy or bleeding diathesis",
        "use of therapeutic anticoagulation",
        "urine protein:creatinine ratio",
        "history of cerebrovascular accident",
        "history of peripheral vascular disease",
        "history of cardiovascular disease",
        "history of abdominal fistula or gastrointestinal perforation",
        "presence of non-healing wound",
        "ulcer",
        "or bone fracture",
        "history of major surgical procedure",
        "history of other malignancy",
        "participation in an experimental drug study",
        "pregnancy or nursing status",
        "presence of sensory neuropathy"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Prior anthracycline exposure, Absolute neutrophil count (ANC), Platelet count, Hemoglobin (Hgb), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin, Creatinine, INR, APTT, Urine protein:creatinine ratio, History of hypertension, History of cardiovascular disease, History of coagulopathy, History of cerebrovascular accident, History of peripheral vascular disease, History of abdominal fistula, History of gastrointestinal perforation, History of non-healing wound, History of other malignancy, Sensory neuropathy grade,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) status",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Weight",
        "Menopausal status",
        "Time from First Documented Metastasis/Relapse to Study Entry",
        "Dominant Current Site of Metastasis/Relapse"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Prior anthracycline exposure",
        "Absolute neutrophil count (ANC)",
        "Platelet count",
        "Hemoglobin (Hgb)",
        "Aspartate aminotransferase (AST)",
        "Alanine aminotransferase (ALT)",
        "Total bilirubin",
        "Creatinine",
        "INR",
        "APTT",
        "Urine protein:creatinine ratio",
        "History of hypertension",
        "History of cardiovascular disease",
        "History of coagulopathy",
        "History of cerebrovascular accident",
        "History of peripheral vascular disease",
        "History of abdominal fistula",
        "History of gastrointestinal perforation",
        "History of non-healing wound",
        "History of other malignancy",
        "Sensory neuropathy grade"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group (ECOG) performance status, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Hemoglobin, Absolute Neutrophil Count, Platelets, Aspartate Aminotransferase, Alanine Aminotransferase, Total Bilirubin, Creatinine, Prior chemotherapy, Prior radiotherapy, Prior hormone therapy, HER-2 status, Left Ventricular Ejection Fraction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) status",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Weight",
        "Menopausal status",
        "Time from First Documented Metastasis/Relapse to Study Entry",
        "Dominant Current Site of Metastasis/Relapse"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelets",
        "Aspartate Aminotransferase",
        "Alanine Aminotransferase",
        "Total Bilirubin",
        "Creatinine",
        "Prior chemotherapy",
        "Prior radiotherapy",
        "Prior hormone therapy",
        "HER-2 status",
        "Left Ventricular Ejection Fraction"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, race, ECOG performance status, HER-2 status, prior anthracycline exposure, prior adjuvant chemotherapy, time since diagnosis of metastatic disease, number and location of metastatic sites, measurable disease size, left ventricle ejection fraction, absolute neutrophil count, platelets, hemoglobin, aspartate aminotransferase, alanine aminotransferase, total bilirubin, creatinine, International Normalized Ratio, activated partial thromboplastin time.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Female"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) status",
          "ECOG performance status"
        ],
        [
          "Time from First Documented Metastasis/Relapse to Study Entry",
          "time since diagnosis of metastatic disease"
        ],
        [
          "Dominant Current Site of Metastasis/Relapse",
          "number and location of metastatic sites"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Weight",
        "Menopausal status"
      ],
      "remaining_candidate_features": [
        "race",
        "HER-2 status",
        "prior anthracycline exposure",
        "prior adjuvant chemotherapy",
        "measurable disease size",
        "left ventricle ejection fraction",
        "absolute neutrophil count",
        "platelets",
        "hemoglobin",
        "aspartate aminotransferase",
        "alanine aminotransferase",
        "total bilirubin",
        "creatinine",
        "International Normalized Ratio",
        "activated partial thromboplastin time."
      ]
    }
  }
}